Letter regarding Zhao et al. entitled “ gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia”

by Maarten J Deenen, Linda M Henricks, Gabe S Sonke, Jan HM Schellens, Didier Meulendijks
Published 2017-05-01

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

by Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema
Published 2019-12-01

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

by Yang Yu, kyriaki Tzogani, Tomas Salmonson, Christian Gisselbrecht, Francesco Pignatti, Didier Meulendijks, Carla Herberts, Paula Hennik, Remy Verheijen, Torunn Wangen, Gro Dahlseng Håkonsen, Torny Kaasboll, Marianne Dalhus, Bjorg Bolstad
Published 2019-11-01

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

by Daniela Melchiorri, Jonas Bergh, Francesco Pignatti, Didier Meulendijks, Paula Hennik, Bjorg Bolstad, Luca Moscetti, Jorge Camarero, Filip Josephson, Maja Sommerfelt Grønvold, Jan Sjoberg, Mihaela Botezatu, Jorn Mulder, Ana Trullas Jimeno, Nikolaos Zafiropoulos, Harald Enzmann
Published 2020-10-01

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine

by Femke M. de Man, G.D. Marijn Veerman, Esther Oomen-de Hoop, Maarten J. Deenen, Didier Meulendijks, Caroline M.P.W. Mandigers, Marcel Soesan, Jan H.M. Schellens, Esther van Meerten, Teun van Gelder, Ron H.J. Mathijssen
Published 2019-04-01